Overview

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of TQH3821 in adult healthy subjects, which plans to recruit 62 healthy subjects. The main purpose was to evaluate the safety and tolerance of TQH3821 in multiple doses, single and multiple times in healthy subjects and in combination with methotrexate tablets.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Treatments:
Methotrexate